Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (451-460 of 566) with videos related to

Pageof 57
Sort By:
American Journal of Hematology|March 18, 2017
Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosisNidhi Tandon, Surbhi Sidana, Morie A Gertz, et al.
Blood Advances|February 17, 2021
Prognostic restaging after treatment initiation in patients with AL amyloidosisNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
Leukemia|November 24, 2019
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosisEli Muchtar, Morie A Gertz, Taxiarchis V Kourelis, et al.
Blood|October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 1, 2018
Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative DisordersLarissa Higgins, Samih H Nasr, Samar M Said, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 13, 2017
Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosisNidhi Tandon, Surbhi Sidana, S Vincent Rajkumar, et al.
Blood Cancer Journal|August 30, 2020
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myelomaAshley Paquin, Alissa Visram, Shaji K Kumar, et al.
Leukemia|November 30, 2019
IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological featuresSurbhi Sidana, Daniel P Larson, Patricia T Greipp, et al.
Blood Advances|April 13, 2019
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosisMohammed A Aljama, M Hasib Sidiqi, Angela Dispenzieri, et al.
Blood|June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseMartha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Pageof 57

Showing results (451-460 of 566) with videos related to

Sort By:
Pageof 57
American Journal of Hematology|March 18, 2017
Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosisNidhi Tandon, Surbhi Sidana, Morie A Gertz, et al.
Blood Advances|February 17, 2021
Prognostic restaging after treatment initiation in patients with AL amyloidosisNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
Leukemia|November 24, 2019
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosisEli Muchtar, Morie A Gertz, Taxiarchis V Kourelis, et al.
Blood|October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 1, 2018
Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative DisordersLarissa Higgins, Samih H Nasr, Samar M Said, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 13, 2017
Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosisNidhi Tandon, Surbhi Sidana, S Vincent Rajkumar, et al.
Blood Cancer Journal|August 30, 2020
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myelomaAshley Paquin, Alissa Visram, Shaji K Kumar, et al.
Leukemia|November 30, 2019
IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological featuresSurbhi Sidana, Daniel P Larson, Patricia T Greipp, et al.
Blood Advances|April 13, 2019
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosisMohammed A Aljama, M Hasib Sidiqi, Angela Dispenzieri, et al.
Blood|June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseMartha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Pageof 57